Navigation Links
Sponges as drugs

Dutch researcher Nicole de Voogd has investigated the possibilities for rearing sea sponges in Indonesia. Some of these sponges contain substances of interest to the pharmaceutical industry. As these are increasingly difficult to obtain, there is growing interest in alternative methods of exploitation, such as rearing sponges.

For her research, De Voogd described three new species of sponges and examined the interactions of four sponge species with possible spatial competitors. She discovered that as soon as certain sponge species grow over corals, the coral develops necrotic tissue. From this she concluded that the sponges concerned produce their bioactive substances to defeat spatial competitors. This is important, as in an environment without spatial competitors, such as in a sponge culture, a lower concentration of the substances of interest to the pharmaceutical industry might be produced.

Sponge culture

The researcher tried to rear 9 of the 151 species of sponge observed but was successful with only 3 species. Although the survival rates of these species were generally very high, the growth rates were very slow and unpredictable. Moreover, the reared sponges produced less of the biologically-active substances than their natural counterparts.

Although Indonesia has a very high diversity of sponge species, and therefore a large number of biologically-active substances with pharmaceutical potential, most of the species occur in relatively low densities compared to species in temperate areas. De Voogd discovered that as a result of this low natural density, surprisingly few Indonesian species are suitable for sea rearing.

Sea rearing

Sedentary marine invertebrates such as sponges, are an important source for a large variety of biologically-active substances. Until more advanced techniques such as chemical synthesis, genetic modification and sponge cell culture are realised, rearing in the sea remains the most reliable
'"/>

Source:Netherlands Organization for Scientific Research


Page: 1 2

Related biology news :

1. Researchers identify target for cancer drugs
2. MetaChip provides quick, efficient toxicity screening of potential drugs
3. Newly discovered pathway might help in design of cancer drugs
4. UNC launches study of liver injury caused by drugs
5. UCLA study assesses cost-effectiveness of Hepatitis B drugs
6. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
7. FDA approves more generic AIDS drugs
8. Virginia Tech group adds tools to DNA-targeted anti-cancer drugs
9. Scientists discover that three molecules may be developed into new Alzheimers drugs
10. Scientists to mimic nature for newest cancer drugs
11. Bacteria are key to green plastics, drugs

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sponges drugs

(Date:12/1/2009)... is pleased to announce the publication of results...e efficacy and tolerability of its novel, intranas...f chronic rhinosinusitis with nasal polyps in Rhi... and European Rhinologic Societies. , Chronic r...se that can significantly reduce a patient,s quali...
(Date:12/1/2009)...s disease, nerve cell degeneration plays a crucial...possibly be derived from steering the generation a...n published in the current issue of the renowned j...rs ago, neurogenesis the process of nerve cell de...adult brain. The textbooks asserted that dead nerv...
(Date:12/1/2009)... University cancer researchers have developed a t...ells and blocks the growth of new tumor blood vess...d to kill cancer cells oncolytic viruses might b...f they also carry a gene for a protein that inhibi...culostatin, is normally produced in the brain. In ...
Breaking Biology News(10 mins):New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2New source discovered for the generation of nerve cells in the brain 2Tumor-attacking virus strikes with 'one-two punch' 2Federal stimulus funding channels more than 2440 million to Fred Hutchinson Cancer Research Center 58955 1Federal stimulus funding channels more than 2440 million to Fred Hutchinson Cancer Research Center 58955 2Federal stimulus funding channels more than 2440 million to Fred Hutchinson Cancer Research Center 58955 3GTRI is developing protocols for testing effects of RFID systems on medical devices 58950 1GTRI is developing protocols for testing effects of RFID systems on medical devices 58950 2GTRI is developing protocols for testing effects of RFID systems on medical devices 58950 3Eating liquorice in pregnancy may affect a childs IQ and behavior 10273 1Eating liquorice in pregnancy may affect a childs IQ and behavior 10273 2
...ng, believed to be one of the detrimental effects ... through effective local management, according to ... long-term recovery of coral reefs in Palau and el...esilient and can bounce back magnificently if subj... so of pristine conditions," says Robert van Woesi...
...e University of California-Davis recently develope...r among bacteria in the environment. Researchers b...s by taking into account characteristics of the na...a hangouts. This model will help scientists to qua...The swapping of genetic material between bacteria ...
...ng for creatures that live in the deepest parts of...one living in the unlikeliest of habitats ?the car...ay that discovering a new sea anemone isn,t so unu... is what sets this new creature apart. , Since ...eren,t sea anemone specialists, they sent the 10 s...
Other Biology News:Palau's coral reefs show differential habitat recovery following the 1998 bleaching event 2Researchers develop way to calculate speed of bacterial sex 2From the deep -- Researchers find new species of sea anemone 2From the deep -- Researchers find new species of sea anemone 3
(Date:12/2/2009)..., JERUSALEM, Israel, December 2 /PRNewswire/...y evaluating the preclinical (animal study) safety...ines technology from Weill,Cornell Medical College...o,treat inherited anemias such as Cooley,s Anemia....technologies to expand, ex vivo,populations of st...
(Date:12/2/2009)..., SINGAPORE, Dec. 2 S*BIO Pte Ltd...ral JAK2 inhibitor, SB1518, at The American Societ... in New Orleans. ,, Data will be presented on t...on trial of SB1518 detailing its safety, tolerabil...ofile in dose levels ranging from 100 to 600 mg. T...
(Date:12/2/2009)... RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall...Company") (OTC Bulletin Board: EMDY), a leading,pr...rmula, milk powder and,soybean products in China, ...in the Spring issue of US Food & Drink Executi... 250,000 executives in the food and beverage indus...
(Date:12/2/2009)... NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Si...any") (NYSE: SCR ), a leading pharmaceutical com...g, and marketing of branded,generic and proprietar...05 of,its drugs have been included in China,s Nati...ssued by China,s Ministry of Human Resources and S...
Breaking Biology Technology:Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
... LELYSTAD, Netherlands, March 3, Genmab A/S (OTC: ...research collaboration aimed at identifying fully,...sease targets.,Intractable targets include those t...ble technologies but are highly desirable for targ...es can for example be due to the,fact that target ...
...3 Vermillion, Inc.,(Nasdaq: VRML ), a high-value...at it has entered into an exclusive license agreem...cialize a novel biomarker panel used to,assess the...d to affect up,to 12 million Americans, PAD is a s...disease can result in severe complications, includ...
...iMedx, Inc., a development-stage,medical device co...n,appointed President. In this role, Mr. Splan wil...o the MiMedx team., Throughout his 34-year career...ity to manage a wide range of operations and deliv...s. Beginning in 1986, Mr. Splan was,employed by Sm...
Other Biology Technology:Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk 2Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk 3MiMedx Announces Brian J. Splan as President 2
Mouse Anti-Rat RT1Bu (Class II Polymorphic) Monoclonal Antibody, Biotin Conjugated from AbD Serotec
Mouse Anti-Guinea Pig T-Cells, Pan Monoclonal Antibody, FITC Conjugated from AbD Serotec
Mouse Anti-Rabbit T LYMPHOCYTES Monoclonal Antibody, Unconjugated, Clone KEN-5 from AbD Serotec
Canine Serum from CHEMICON
Biology Products: